Plant Name: Sequoia sempervirens
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| GPBAR1; ADORA3; ADORA2A; ADORA1; GPR35; | |
| TSHR; | |
| PTPN1; PTPN2; ACP1; PTPRF; | |
| ALPI; RECQL; APOBEC3G; TDP1; ADK; PIK3CG; GLO1; HSD11B1; AKR1B10; AKR1B1; HSD17B10; HPGD; ALDH1A1; ALOX15; USP2; POLB; APEX1; | |
| GAA; ACHE; | |
| TOP2A; | |
| INSR; SYK; FLT3; MYLK; | |
| CA2; CA1; CA12; CA9; CA7; CA14; CA5B; CA5A; CA4; CA6; | |
| RORC; | |
| NR1H4; | |
| KDM4E; | |
| BACE1; | |
| HIF1A; STAT6; | |
| SLC28A2; SLC28A1; SLC28A3; SLCO1B3; SLCO1B1; | |
| XDH; | |
| L3MBTL1; SMN1;SMN2; | |
| THPO; MAPT; APP; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Aspartic protease | BACE1 | Beta-secretase 1 | P56817 | CHEMBL4822 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Enzyme_unclassified | ALPI | Intestinal alkaline phosphatase | P09923 | CHEMBL5573 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | APOBEC3G | DNA dC->dU-editing enzyme APOBEC-3G | Q9HC16 | CHEMBL1741217 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | ADK | Adenosine kinase | P55263 | CHEMBL3589 |
| Enzyme_unclassified | PIK3CG | PI3-kinase p110-gamma subunit | P48736 | CHEMBL3267 |
| Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
| Enzyme_unclassified | HSD11B1 | 11-beta-hydroxysteroid dehydrogenase 1 | P28845 | CHEMBL4235 |
| Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Isomerase | TOP2A | DNA topoisomerase II alpha | P11388 | CHEMBL1806 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Methyl-lysine/arginine binding protein | L3MBTL1 | Lethal(3)malignant brain tumor-like protein 1 | Q9Y468 | CHEMBL1287622 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Nuclear hormone receptor subfamily 1 group F | RORC | Nuclear receptor ROR-gamma | P51449 | CHEMBL1741186 |
| Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Protein Kinase | INSR | Insulin receptor | P06213 | CHEMBL1981 |
| Protein Kinase | SYK | Tyrosine-protein kinase SYK | P43405 | CHEMBL2599 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | MYLK | Myosin light chain kinase, smooth muscle | Q15746 | CHEMBL2428 |
| Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
| Protein Phosphatase | PTPN2 | T-cell protein-tyrosine phosphatase | P17706 | CHEMBL3807 |
| Protein Phosphatase | ACP1 | Low molecular weight phosphotyrosine protein phosphatase | P24666 | CHEMBL4903 |
| Protein Phosphatase | PTPRF | Receptor-type tyrosine-protein phosphatase F (LAR) | P10586 | CHEMBL3521 |
| SLC superfamily of solute carriers | SLC28A2 | Sodium/nucleoside cotransporter 2 | O43868 | CHEMBL5780 |
| SLC superfamily of solute carriers | SLC28A1 | Sodium/nucleoside cotransporter 1 | O00337 | CHEMBL5551 |
| SLC superfamily of solute carriers | SLC28A3 | Solute carrier family 28 member 3 | Q9HAS3 | CHEMBL5707 |
| SLC superfamily of solute carriers | SLCO1B3 | Solute carrier organic anion transporter family member 1B3 | Q9NPD5 | CHEMBL1743121 |
| SLC superfamily of solute carriers | SLCO1B1 | Solute carrier organic anion transporter family member 1B1 | Q9Y6L6 | CHEMBL1697668 |
| Small molecule receptor (family A GPCR) | GPBAR1 | G-protein coupled bile acid receptor 1 | Q8TDU6 | CHEMBL5409 |
| Small molecule receptor (family A GPCR) | ADORA3 | Adenosine A3 receptor | P0DMS8 | CHEMBL256 |
| Small molecule receptor (family A GPCR) | ADORA2A | Adenosine A2a receptor | P29274 | CHEMBL251 |
| Small molecule receptor (family A GPCR) | ADORA1 | Adenosine A1 receptor | P30542 | CHEMBL226 |
| Small molecule receptor (family A GPCR) | GPR35 | G-protein coupled receptor 35 | Q9HC97 | CHEMBL1293267 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | STAT6 | Signal transducer and activator of transcription 6 | P42226 | CHEMBL5401 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | APP | Beta amyloid A4 protein | P05067 | CHEMBL2487 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.157E-10 | 2.519E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 9.651E-10 | 1.617E-06 | AKR1B1, AKR1B10, APP, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, HSD11B1, NR1H4 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 9.068E-09 | 1.106E-05 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:0055114; oxidation-reduction process | 9.144E-09 | 1.106E-05 | AKR1B1, AKR1B10, ALDH1A1, ALOX15, APEX1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, GAA, HPGD, HSD11B1, HSD17B10, KDM4E, XDH |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.111E-08 | 1.273E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.582E-08 | 1.723E-05 | ALPI, APOBEC3G, CA1, CA12, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9, GLO1, L3MBTL1, NR1H4, PTPN1, RORC |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 9.017E-08 | 7.272E-05 | ALOX15, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, XDH |
| CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 2.870E-07 | 1.953E-04 | ADORA1, CA2, CA4, CA9, HPGD, SLCO1B1, SLCO1B3, TSHR |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 8.283E-07 | 4.625E-04 | CYP1A2, CYP2C19, CYP2C9 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.183E-06 | 5.852E-04 | CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0060089; molecular transducer activity | GO:0001609; G-protein coupled adenosine receptor activity | 1.446E-06 | 6.297E-04 | ADORA1, ADORA2A, ADORA3 |
| BP | GO:0008152; metabolic process | GO:1901615; organic hydroxy compound metabolic process | 1.761E-06 | 7.518E-04 | AKR1B1, AKR1B10, ALDH1A1, ALOX15, APP, CYP19A1, CYP1A1, CYP1B1, HIF1A, NR1H4 |
| BP | GO:0008152; metabolic process | GO:0070988; demethylation | 2.012E-06 | 8.266E-04 | APEX1, CYP1A1, CYP1A2, CYP2C9, KDM4E |
| BP | GO:0032501; multicellular organismal process | GO:0048143; astrocyte activation | 3.453E-06 | 1.296E-03 | ADORA2A, APP, MAPT |
| BP | GO:0009987; cellular process | GO:0001973; adenosine receptor signaling pathway | 3.453E-06 | 1.296E-03 | ADORA1, ADORA2A, ADORA3 |
| BP | GO:0050896; response to stimulus | GO:0010035; response to inorganic substance | 4.672E-06 | 1.647E-03 | AKR1B1, ALOX15, APEX1, APP, CA2, CYP1A1, CYP1A2, CYP1B1, HIF1A, STAT6 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 5.886E-06 | 1.913E-03 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 6.015E-06 | 1.926E-03 | CYP19A1, CYP1A1, CYP2C19, CYP2C9 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 8.974E-06 | 2.669E-03 | CYP1A2, CYP2C19, CYP2C9 |
| BP | GO:0051179; localization | GO:0044070; regulation of anion transport | 1.030E-05 | 2.991E-03 | ADORA1, ADORA2A, CA2, CA7, SYK |
| BP | GO:0023052; signaling | GO:0032230; positive regulation of synaptic transmission, GABAergic | 1.164E-05 | 3.243E-03 | ADORA2A, CA2, CA7 |
| BP | GO:0051179; localization | GO:0015860; purine nucleoside transmembrane transport | 1.221E-05 | 3.243E-03 | SLC28A2, SLC28A3 |
| BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 1.221E-05 | 3.243E-03 | APEX1, POLB |
| MF | GO:0005215; transporter activity | GO:0015389; pyrimidine- and adenine-specific:sodium symporter activity | 1.221E-05 | 3.243E-03 | SLC28A1, SLC28A3 |
| MF | GO:0005215; transporter activity | GO:0015211; purine nucleoside transmembrane transporter activity | 1.221E-05 | 3.243E-03 | SLC28A2, SLC28A3 |
| BP | GO:0008152; metabolic process | GO:0017144; drug metabolic process | 1.498E-05 | 3.838E-03 | ACHE, ADK, AKR1B1, AKR1B10, ALDH1A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| MF | GO:0003824; catalytic activity | GO:0016903; oxidoreductase activity, acting on the aldehyde or oxo group of donors | 1.715E-05 | 4.292E-03 | AKR1B1, AKR1B10, ALDH1A1, XDH |
| CC | GO:0044464; cell part | GO:0030673; axolemma | 2.261E-05 | 5.533E-03 | ADORA1, ADORA2A, MAPT |
| BP | GO:0048511; rhythmic process | GO:0042752; regulation of circadian rhythm | 2.455E-05 | 5.874E-03 | ADORA1, ADORA2A, RORC, TOP2A, USP2 |
| BP | GO:0008152; metabolic process | GO:2000377; regulation of reactive oxygen species metabolic process | 2.868E-05 | 6.715E-03 | CYP1B1, HIF1A, INSR, MAPT, SYK, XDH |
| BP | GO:0051179; localization | GO:1904823; purine nucleobase transmembrane transport | 3.655E-05 | 7.580E-03 | SLC28A1, SLC28A3 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 3.655E-05 | 7.580E-03 | CA2, CA7 |
| BP | GO:0051179; localization | GO:0015855; pyrimidine nucleobase transport | 3.655E-05 | 7.580E-03 | SLC28A1, SLC28A3 |
| BP | GO:0009987; cellular process | GO:0038183; bile acid signaling pathway | 3.655E-05 | 7.580E-03 | GPBAR1, NR1H4 |
| MF | GO:0060089; molecular transducer activity | GO:0038181; bile acid receptor activity | 3.655E-05 | 7.580E-03 | GPBAR1, NR1H4 |
| CC | GO:0044464; cell part | GO:0099056; integral component of presynaptic membrane | 3.655E-05 | 7.580E-03 | ADORA1, ADORA2A |
| BP | GO:0008152; metabolic process | GO:0034754; cellular hormone metabolic process | 3.922E-05 | 7.907E-03 | AKR1B1, ALDH1A1, CYP19A1, CYP1A1, CYP1B1 |
| MF | GO:0003824; catalytic activity | GO:0042578; phosphoric ester hydrolase activity | 4.223E-05 | 8.360E-03 | ACP1, ADORA1, ALPI, APEX1, PTPN1, PTPN2, PTPRF, TDP1 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 4.333E-22 | 9.434E-18 | CA1, CA12, CA14, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 3.307E-16 | 2.400E-12 | CA1, CA12, CA14, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 4.183E-15 | 1.518E-11 | CA1, CA12, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 1.972E-21 | 2.563E-19 | CA12; CA1; CA5B; CA2; CA5A; CA4; CA7; CA6; CA9; CA14 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 3.525E-07 | 2.291E-05 | HSD11B1; CYP2C9; CYP1A2; CYP1A1; CYP1B1; CYP2C19 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 1.559E-06 | 6.756E-05 | HSD11B1; CYP1A2; CYP1A1; CYP1B1; CYP19A1 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 1.380E-05 | 2.991E-04 | GAA; ALOX15; ADK; AKR1B1; CYP2C19; CYP19A1; HSD17B10; HSD11B1; CYP2C9; AKR1B10; CYP1A2; ALDH1A1; CYP1A1; ALPI; XDH |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 4.914E-06 | 1.278E-04 | HSD11B1; CYP2C9; CYP1A2; CYP1A1; CYP1B1 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 2.722E-06 | 8.847E-05 | CYP2C9; CYP1A2; ALOX15; CYP2C19 |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 2.502E-05 | 4.646E-04 | INSR; CYP1A1; CYP1B1; CYP19A1 |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 3.929E-05 | 6.384E-04 | INSR; ADORA1; TSHR; PIK3CG |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 7.078E-05 | 1.022E-03 | CYP2C9; CYP1A2; ALDH1A1; CYP1A1 |
| hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 1.176E-04 | 1.273E-03 | PTPN1; INSR; ACP1; PTPRF |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 1.000E-04 | 1.273E-03 | SLCO1B1; CA2; SLCO1B3; NR1H4 |
| hsa04022 | cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | 2.606E-04 | 2.420E-03 | ADORA3; INSR; ADORA1; PIK3CG; MYLK |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 5.199E-04 | 4.224E-03 | PTPN1; INSR; PTPRF; PIK3CG |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 5.760E-04 | 4.404E-03 | CYP2C9; APP; ALOX15; CYP2C19 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 3.394E-04 | 2.942E-03 | CYP1A2; CYP1A1; CYP1B1 |
| hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 1.289E-03 | 8.822E-03 | PTPN1; INSR; PTPRF; PIK3CG |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 1.232E-03 | 8.822E-03 | CYP2C9; ALOX15; CYP2C19 |
| hsa04630 | Jak-STAT signaling pathway_Homo sapiens_hsa04630 | 2.062E-03 | 1.218E-02 | THPO; STAT6; PTPN2; PIK3CG |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 1.429E-04 | 1.429E-03 | AKR1B10; GAA; AKR1B1 |
| hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 2.516E-03 | 1.395E-02 | ADORA2A; GPR35; ADORA3; ADORA1; TSHR |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 1.541E-03 | 1.002E-02 | FLT3; HIF1A; PIK3CG |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 2.576E-03 | 1.395E-02 | BACE1; APP; MAPT; HSD17B10 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 1.678E-03 | 1.039E-02 | CYP2C9; CYP1A2; CYP2C19 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 4.715E-03 | 2.357E-02 | ADORA2A; ADORA1; TSHR; PIK3CG |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 5.216E-03 | 2.456E-02 | INSR; HIF1A; PIK3CG |
| hsa04611 | Platelet activation_Homo sapiens_hsa04611 | 8.319E-03 | 3.277E-02 | SYK; PIK3CG; MYLK |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 7.952E-03 | 3.230E-02 | ADORA3; ADORA1; PIK3CG |
| hsa04072 | Phospholipase D signaling pathway_Homo sapiens_hsa04072 | 1.303E-02 | 4.838E-02 | SYK; INSR; PIK3CG |
| hsa04930 | Type II diabetes mellitus_Homo sapiens_hsa04930 | 1.162E-02 | 4.442E-02 | INSR; PIK3CG |
| hsa04960 | Aldosterone-regulated sodium reabsorption_Homo sapiens_hsa04960 | 7.783E-03 | 3.230E-02 | INSR; PIK3CG |
| hsa00040 | Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | 6.660E-03 | 2.886E-02 | AKR1B10; AKR1B1 |
| hsa00051 | Fructose and mannose metabolism_Homo sapiens_hsa00051 | 5.290E-03 | 2.456E-02 | AKR1B10; AKR1B1 |
| hsa03410 | Base excision repair_Homo sapiens_hsa03410 | 5.619E-03 | 2.519E-02 | POLB; APEX1 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 2.752E-03 | 1.431E-02 | CA2; CA4 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 1.132E-04 | 1.273E-03 | CYP1A2; XDH |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | APP |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | INSR; HIF1A; CA9; PIK3CG; PIK3CG |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1 |
| C00-D49: Neoplasms | Endometrial cancer | C54.1 | PIK3CG; PIK3CG |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| NA: NA | Edema | NA | CA2 |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1 |
| I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | PIK3CG |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
| C00-D49: Neoplasms | Prostate cancer | C61 | FLT3; PIK3CG |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Lipid metabolism disorder | E75-E78 | HSD11B1 |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1; MYLK |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | SYK |
| NA: NA | Hepatitis C virus infection | NA | ADORA3 |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | ADORA3 |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| C00-D49: Neoplasms | Diffuse large B-cell lymphoma | C83.3 | PIK3CG |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; ACHE; CA4 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ADORA1; ACHE; MAPT |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| C00-D49: Neoplasms | CLL | NA | FLT3 |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | INSR; ADORA2A; ADK; ACHE |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | FLT3 |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ADORA2A; ADORA1; ACHE |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | ADORA2A |
| G00-G99: Diseases of the nervous system G00-G99 | Diagnostic imaging | G30, I73.9 | APP |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ADORA3 |
| C00-D49: Neoplasms | Ocular cancer | C69 | APEX1 |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | HSD11B1; CA4; CA4 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | INSR; HSD11B1 |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hunter syndrome | E76.1 | INSR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | PTPN1; INSR; HSD11B1; HSD11B1; ADORA1; AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperglycaemia in type 2 diabetes | E11, R73.9 | INSR |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1; ACHE |
| C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1 |
| I00-I99: Diseases of the circulatory system | Orthostatic hypotension | I95.1 | ADORA1 |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ADORA2A |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADORA2A; ADORA1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | INSR; ADORA1 |
| K00-K95: Diseases of the digestive system | Crohn's disease | K50 | INSR |
| N00-N99: Diseases of the genitourinary system | Renal failure | N17, N18, N19 | ADORA1 |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
| C00-D49: Neoplasms | Cancer | C00-C96 | ADORA3; SYK; HIF1A; CA1; FLT3; FLT3; CA9; PIK3CG; APP; ACHE |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Radionuclide imaging | W88 | ADORA2A |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | PIK3CG |
| I00-I99: Diseases of the circulatory system | Cardiac arrhythmias | I47-I49 | ADORA1; ADORA1 |
| I00-I99: Diseases of the circulatory system | Cardiac disease | I00-I99 | ADORA1 |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
| C00-D49: Neoplasms | Glioma | C71 | PIK3CG; APP |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
| NA: NA | Geographic retinal atrophy | NA | APP |
| NA: NA | GIST | NA | FLT3 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ADORA3; ADORA2A; ADORA1; CA1; CA1; AKR1B1; ACHE |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | XDH; AKR1B1 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | SYK; HIF1A; FLT3; CA9; PIK3CG; TOP2A |
| C00-D49: Neoplasms | B-cell lymphoma | C85.1 | SYK |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3 |
| C00-D49: Neoplasms | Breast cancer | C50 | INSR; CYP19A1; FLT3; FLT3; CA9; PIK3CG |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1 |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | ADORA1; XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTPN1; PTPN1; GPBAR1; INSR; HSD11B1; PIK3CG; PIK3CG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1/2 diabetes | E08-E13 | INSR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | INSR |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| NA: NA | Colour dead tissues | NA | PTPN1 |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | FLT3 |
| NA: NA | Upper abdominal bloating | NA | ACHE |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | APP |
| E00-E89: Endocrine, nutritional and metabolic diseases | Atrial fibrillation | E78, I48 | ADORA1; ADORA1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | INSR; SYK; ADORA1 |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9; PIK3CG |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
| A00-B99: Certain infectious and parasitic diseases | Sepsis | A40, A41 | ADORA1 |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ADORA1 |
| I00-I99: Diseases of the circulatory system | Acute and chronic heart failure | I50 | ADORA1 |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | HSD11B1 |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | SYK; SYK; ADORA2A; ADORA1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PIK3CG |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | ADORA2A |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | SYK; AKR1B1 |
| I00-I99: Diseases of the circulatory system | Cerebral amyloid angiopathy | I68.0 | APP |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SYK |
| C00-D49: Neoplasms | Hematologic malignancies | C81-C86 | PIK3CG |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | SYK; ADORA1 |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | INSR; APP; ACHE; ACHE; ACHE; MAPT |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ADORA2A |
| C00-D49: Neoplasms | AML | NA | FLT3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypertriglyceridemia | E78.1, E78.2, E78.3, I47-I49 | ADORA1 |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | SYK |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3 |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | PIK3CG; PIK3CG |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
| H00-H59: Diseases of the eye and adnexa | Age related macular degeneration | H35.3 | APP |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | ADORA3 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Convulsions | R56.0 | ADK |
| I00-I99: Diseases of the circulatory system | Coronary disorder diagnosis | I20-I25 | ADORA2A |
| NA: NA | Angioedema | NA | PIK3CG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ADORA3 |
| G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | APP |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | APP; ACHE |
| A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | APP |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | PIK3CG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | GPBAR1; HSD11B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic syndrome x | E88.81 | HSD11B1 |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ADK; ACHE |
| J00-J99: Diseases of the respiratory system | Influenza virus | J11.1 | HSD11B1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Fatigue | R53 | ADORA1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | FLT3; FLT3 |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | ADORA2A; ADORA1 |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | APP |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; MAPT |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | ADORA3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypoglycemia | E16.0-E16.2 | INSR |
| C00-D49: Neoplasms | Non-hodgkin's lymphoma | C85 | SYK; PIK3CG; PIK3CG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | INSR; HSD11B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PTPN1; HSD11B1 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | SYK; PIK3CG |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
| NA: NA | Enthesopathy | NA | PIK3CG |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | ADK |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |